Tim Fischell, MD, FACC

CEO & Chief Medical Officer

A practicing interventional cardiologist, prolific inventor and entrepreneur, Dr. Fischell is currently Professor of Medicine at Michigan State and Medical Director of the Borgess Heart Institute Department of Cardiovascular Research and the Interventional Cardiology Fellowship Program. An inventor and co-inventor on over 70 patented devices, he co-designed the stent upon which the J&J drug-eluting stent platform is based. Co-founder of several biomedical start-up companies (Angel Medical Systems, Svelte, Ostial Solutions, etc.), his honors include the Thorax Center Andreas Gruentzig Award for Inventor of the Year in 1997. Dr. Fischell has presented over 200 papers and authored more than 110 articles in peer-reviewed journals and 20 book chapters.
Nicole Haratani, BSN, RN

Exec. VP, Global Clinical, Regulatory Affairs and Quality

Nicole’s extensive background includes clinical and regulatory expertise in medical device and combination products. Prior to Ablative Solutions, Inc., she was Vice President of Clinical Affairs at Guided Delivery Systems. She held director or senior director positions with Boston Scientific, Sadra Medical, and the Cardiovascular Research Foundation. Her clinical affairs experience includes Abbott Vascular, Guidant, and St. Jude Medical. She has co-authored numerous scientific papers and presented at multiple medical device conferences. Nicole has a background of nursing with experience in trauma, cardiac cath lab, and cardiac surgery ICU.
Darrin Kent

VP, R&D and Operations

An experienced R&D leader, Darrin has 20 years of experience in the medical device industry designing and commercializing dozens of devices.   He has honed his management, engineering, pre-clinical research and manufacturing skills at REV·1 Engineering, a contract design and development firm. Prior to that, he developed innovative endovascular devices at Sequent Medical (later Terumo) and Guidant Vascular Intervention (later Abbott Vascular). Darrin has a BSE from Cal Poly, SLO and he is a named inventor on 30 US patents, granted or pending.
Michaun Auzenne

VP, Finance and HR

Michaun has over 20 years of diverse accounting and financial management experience with both private and public companies. Before joining Ablative Solutions, Michaun held management positions at KLA-Tencor, NetApp and most recently as Corporate Controller with Ancora Heart, Inc. (formerly Guided Delivery Systems, Inc.) In her current role with Ablative Solutions, Inc., her responsibilities include forecasting, financial analysis, cash management, human resources, financial reporting and fundraising.
Helen Parise, PhD

Acting VP, Biometrics

With over 20 years of experience in medical research and clinical trials, Helen Parise has collaborated on the design, implementation and analysis of global clinical studies and research driven investigations as a Research Assistant Professor at Boston University, Director of Biostatistics at Veristat, Inc., a CRO, and more recently as Director of Biometrics, Executive Director of the Clinical Trials Center and Chief Statistical Officer at the Cardiovascular Research Foundation and Columbia University School of Medicine. With a doctorate in Biostatistics from Harvard University School of Public Health, Helen has over 100 collaborative publications and has given numerous talks on the nuances of cardiovascular device trials.
Jill Amstutz

Acting VP, Clinical Marketing

With over 25 years of experience in the medical device industry, Jill leverages strategic marketing skills as a collaborative project leader for early stage medical device companies. She most recently served as VP Global Marketing at Neuravi, an innovator in stroke treatment based on clot science that was acquired by J&J. As part of the early team at Sadra Medical, which was acquired by Boston Scientific, she played a leadership role in developing Lotus University. Jill has an MBA from the Stanford GSB and a BA from Princeton University.

Board of Directors

David Fischell, PhD (Chairman)

CEO, Angel Medical Systems – Shrewsbury, NJ

Steven Almany, MD, FACC

Corporate Vice Chief of Cardiology, William Beaumont Hospital – Royal Oak, MI

Paul Buckman

General Manager – TMVR, LivaNova PLC

Dale Grogan

Managing Director, Michigan Accelerator Fund

Tim Fischell, MD, FACC

CEO & CMO, Ablative Solutions – Kalamazoo, MI

We are proud to work with some of the most committed innovators in the industry.

Scientific Advisory Board (Global)

Gregg W. Stone, MD, FACC, FSCAI

Chairman of Publication Committee, Director of Cardiovascular Research and Education, Columbia University Medical Center / New York-Presbyterian Hospital

Steven Almany, MD, FACC

Corporate Vice Chief of Cardiology, William Beaumont Hospital – Royal Oak, MI

Prof. Peter J. Blankestijn

University Medical Center Utrecht, The Netherlands

Maurice Buchbinder, MD, FACC

Medical Director, Foundation for Cardiovascular Medicine

Dean J. Kereiakes, MD, FACC, FSCAI

Medical Director, The Christ Hospital Heart and Vascular Center

Prof. Melvin Lobo

Director, Barts Blood Pressure Centre of Excellence, London, UK

Prof. Dr. med. Felix Mahfoud

Department of Internal Medicine and Cardiology, University Hospital of the Saarland, Germany

Prof. Atul Pathak

Head of Clinical Research, Hypertension, Heart Failure Clinic, Clinique Pasteur, Toulouse, France

Prof. Dr. med. Roland E. Schmieder

Head of the Clinical Research Center (CRC), University   Hospital Erlangen, Germany

Michael Weber, MD, FACP, FACC, FAHA

Professor of Medicine at SUNY Downstate College of Medicine, Brooklyn, NY